LOGIN  |  REGISTER
Terns Pharmaceuticals
Amneal Pharmaceuticals

RxSight to Participate in Upcoming Morgan Stanley and Wells Fargo Healthcare Conferences

August 22, 2024 | Last Trade: US$12.60 0.45 -3.45

ALISO VIEJO, Calif., Aug. 22, 2024 (GLOBE NEWSWIRE) -- RxSight, Inc. (NASDAQ: RXST) an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced its plans to participate in two upcoming healthcare conferences in September.

  • Morgan Stanley 22nd Annual Global Healthcare Conference
    - Fireside Chat: Wednesday, September 4, 2024, at 9:15 a.m. ET in New York City, NY
  • Wells Fargo 2024 Healthcare Conference
    - Fireside Chat: Thursday, September 5, 2024, at 3:45 p.m. ET in Boston, MA

Interested parties may access live and archived webcasts of these events at https://investors.rxsight.com/.

About RxSight, Inc.

RxSight, Inc. is an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery. The RxSight® Light Adjustable Lens system, comprised of the RxSight Light Adjustable Lens® (LAL™/LAL+™, collectively the “LAL”), RxSight Light Delivery Device (LDD™) and accessories, is the first and only commercially available intraocular lens (IOL) technology that can be adjusted after surgery, enabling doctors to customize and deliver high-quality vision to patients after cataract surgery. Additional information about RxSight can be found at www.rxsight.com.

Company Contact:
Shelley B. Thunen
Chief Financial Officer
This email address is being protected from spambots. You need JavaScript enabled to view it.

Investor Relations Contact:
Oliver Moravcevic
VP, Investor Relations
This email address is being protected from spambots. You need JavaScript enabled to view it.

Stock Quote

Featured Stock

Compass Therapeutics

Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...

CLICK TO LEARN MORE

Featured Stock

Terns Pharmaceuticals

Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page